Illumina, Inc., Thermo Fisher Scientific and Eurofins Scientific are Dominating the global Whole Exome Sequencing Market in 2021

Global Whole Exome Sequencing Market is expected to grow with the CAGR of 19.0% in the forecast period of 2022 to 2029. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-whole-exome-sequencing-market

Global whole exome sequencing market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in global whole exome sequencing market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement into the market. This helped companies to maximize the sales with enhanced product portfolio.

For instance

  • In November 2020, Illumina, Inc. had extended the use of NextSeq 2000 Sequencing System with the commercial availability of the P3 high-output flow cell which has the ability to offer 1.1 billion reads in single sequencing run. This expanded range of application of existing product enhanced the company’s product sales and helped it to attain lucrative growth in the market

Illumina Inc. is the dominating player in global whole exome sequencing market. The other key players existing in the market includes Beckman Coulter, Inc., BIONEER CORPORATION., Eurofins Scientific, ExoDx, FOUNDATION MEDICINE, INC., PerkinElmer Genomics (A Subsidiary of PerkinElmer Inc.), QIAGEN, GeneFirst Limited., -CeGaT GmbH, Illumina, Inc., Meridian Group International, Merck KGaA, SOPHiA GENETICS, Azenta US, CD Genomics, Twist Bioscience., Thermo Fisher Scientific, Inc., GeneDx, LLC, Psomagen, Integrated Data Technology, Inc. among others.

Illumina, Inc.

 Illumina, Inc. headquartered in California, U.S. was founded in the year 1998. The company is focusing applying innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. The company has two business segments including Core Illumina and GRAIL among which Core Illumina is the market focused segment. The company is providing products via Instruments, kits & reagents and services, among these services is the market focused category. The company is engaged in continuous development of whole exome sequencing.

For instance,

  • In December 2020, Illumina Inc., signed a risk sharing agreement with Harvard Pilgrim Health Care in order to make available whole-genome sequencing to Harvard Pilgrim members. The program availability enhanced the diagnosis rate of genetic diseases among children, which has eliminated the extra costs and improved the overall patients outcomes.

The company has wide presence across Europe, Americas, Middle East & Africa, and Asia-Pacific. The company has various subsidiaries including Illumina Scientific Co Ltd (China), Illumina GmbH (Germany), Illumina Rus (Russia), Illumina AB (Sweden) among others.

Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. was founded in 1956. The company is focusing on accelerate research in life science solutions, solve complex analytical challenges, improve patient diagnostics, drive innovation and increase laboratory productivity. The company is providing products via several business segments including Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products & Biopharma Services among which Life Science Solutions is market focused category. The company is providing products via several product categories including Life Sciences, Industrial & Applied Sciences, Clinical & Diagnostics, Lab Solutions and Digital Solutions. The market focus products lie under Life Sciences product category.

For instance,

  • In May 2022, Thermo Fisher Scientific Inc. went under partnership with Qatar Genome Program (QGP) a member of Qatar Foundation (QF) with the goal of accelerating the genomic research and clinical outcomes. This initiative expanded the benefits of precision medicine across Arab populations globally.

The company has wide presence across Europe, Americas, Middle East & Africa, and Asia-Pacific. The company has various subsidiary companies including Thermo Electron Pty Limited (Australia), Thermo Suomi Holding B.V. (Netherlands), Thermo Electron LLS Private Limited (India), among others.

Whole Exome Sequencing Market

Eurofins Scientific

Eurofins Scientific headquartered in Val Fleuri, Luxembourg was founded in 1987. The company is focusing on providing customers with innovative and high-quality laboratory, research and advisory services. The company is engaged in providing products via several product categories including Agroscience Services, Agro Testing, Assurance, BioPharma Services, Clinical Diagnostics, Consumer Product Testing, Cosmetics & Personal Care, Environmet Testing, Food & Feed Testing, Forensic Services, Genomic Services, Maritime Services, Material & Engineering, REACH Services, Sensory & Consumer Research, Eurofins Technologies among which Genomic Services is the market focused category.

The company has wide presence across Europe, Asia Pacific, Americas, and Middle East & Africa. The company has two subsidiaries including Lancaster Laboratories (U.S.), Eurofins Biomnis (France), Eurofins Food Testing UK Limited (England), among others.